Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The Role of Sleep in Protecting Spatial Memories From Age-Related Decline

10 novembre 2026 mis à jour par: Eitan Schechtman, University of California, Irvine

Healthy aging is characterized by impaired spatial memory compared to younger adults. These impairments not only negatively impact quality of life but are also an early marker for the onset of dementia, especially Alzheimer's Disease. While sleep plays an active role in spatial memory consolidation in young adults, the extent to which sleep contributes to this process in aged adults is yet to be determined. The objective of this developmental R21 project is to determine the impact of sleep on spatial memory in cognitively healthy, aged adults, and evaluate the potential for a sleep intervention targeting memory reactivation to improve performance in this population. The project will include a single experiment using an ecologically valid ambulatory virtual environment to test the effects of sleep on spatial memory performance in aged adults.

Aim 1 will determine whether post-learning sleep benefits spatial memory in aged adults, more so than a period of wakefulness. Spatial memory performance will be measured using well-established tasks in a virtual environment, before and after a 90-minute delay consisting of either an EEG-monitored nap or wakefulness. Changes in performance between these two conditions will be measured after the 90-minute delay and again one week later. The key hypothesis for this aim is that post-learning sleep will improve spatial memory recall more than an equivalent period of wakefulness, and that this improvement will correlate with sleep stages and EEG waveforms that are linked with memory consolidation.

Aim 2 will test whether targeted memory reactivation, a technique used to bias memory consolidation by obtrusively presenting sounds during sleep, can be used to enhance spatial memory in aged adults. To this end, task-related sounds will be presented to participants during a nap immediately after learning and during nocturnal sleep over the following week. Spatial memory performance will be compared between this group and a sleep group for which no sounds will be presented during sleep. The key hypotheses are that this manipulation will improve spatial memory performance, and that these behavioral effects will be mediated by memory-related EEG waveforms elicited by sounds presented during sleep.

By combining sleep, high-density electrophysiology, and a realistic testing environment, this project will determine the benefit of sleep on spatial memory in aged adults and test ways to leverage sleep to make consolidation more efficient. Results will inform our understanding of sleep-dependent consolidation in aged adults and pave the way for scalable, non-invasive treatments to improve day-to-day life and provide critical protections against dementia.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

126

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Eitan Schechtman-Drayman
  • Numéro de téléphone: 847-722-9220
  • E-mail: eitans@uci.edu

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion:

  1. Age >=60.
  2. Montreal Cognitive Assessment score above 25.
  3. Good general health with no disease or conditions expected to interfere with the study.
  4. Fluent in English.
  5. Fully ambulatory without the use of a cane, walker, or wheelchair.
  6. Believe they will be able to fall asleep in a lab setting for an afternoon nap.

Exclusion:

  1. No history or current diagnosis of psychiatric disorders.
  2. No history or current neurological disease.
  3. No current sleep disorder, including sleep apnea and insomnia.
  4. No snoring during sleep.
  5. No uncorrected hearing, visual or motor impairment.
  6. No changes in medication usage over the past month and no plans to make such changes over the course of the study.

All inclusion/exclusion criteria, except for the Montreal Cognitive Assessment, will be based on self-report.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Wake group

Participants watch a feature-length film ("Stand By Me") in the study room for 90 minutes. They are instructed to remain awake and alert throughout. The experimenter monitors wakefulness from the control room via a baby monitor and a real-time EEG display. If EEG signs of non-rapid-eye-movement-sleep (NREM) Stage 1 or deeper sleep onset are observed, the participant is prompted to remain awake.

Comparateur actif: Sleep group

Participants are given a 90-minute nap opportunity in a darkened sleep room (bed, clean linens, blanket) with low-volume white noise delivered via earphones. EEG (electroencephalography) with EOG (electrooculography) and EMG (electromyography) is recorded continuously. During NREM sleep, auditory cues that are unrelated to the virtual reality (VR) task are delivered. Once the experimenter confirms via real-time EEG that the participant is in NREM Stage 2 or Stage 3 sleep, non-task-associated auditory cues are delivered via a speaker at a volume calibrated individually during a Sound Volume Test before the nap - the lowest volume at which the participant can reliably detect the sound while awake. Following the nap, participants may shower or wash up in a private room with a sink.

This group will be allowed to sleep shortly after learning.

Expérimental: Sleep+TargetedMemoryReactivation (TMR) Group

Participants follow the same nap protocol as the Sleep group, except that task-relevant sounds are presented during sleep. A minimum of 6 successful cue presentations during the nap is required for inclusion in TMR-specific analyses.

This group will be allowed to sleep shortly after learning.

The researchers will unobtrusively and repeatedly present a sound that was linked with a spatial task during sleep. This method was shown to improve memory in various tasks. The sounds will be presented both in the lab and at home. In both cases, the sounds will be presented during non-REM sleep stages 2 and 3. The sounds will only be presented to the Sleep+TMR group (N = 42).

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Performance on spatial memory task - wayfinding task
Délai: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Accuracy will be measured (percent of correct trials)

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week
Performance on spatial memory task - pointing task
Délai: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Angular error will be measured (averaged over trials)

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Performance on other memory tasks - paired-associates task
Délai: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

The researchers will use the paired-associates task to examine the effects of sleep on declarative memories. Percent correct pairs will be used.

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week
Performance on other memory tasks - serial reaction time task
Délai: Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

The researchers will use the serial reaction time task to examine the effects of sleep on non-declarative memories. The number of correct sequences will be used.

Measured at baseline, approximately 2 hours later (after the delay, which includes wakefulness, sleep, or sleep with targeted memory reactivation), and after 1 week

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

5 novembre 2026

Achèvement primaire (Estimé)

31 mars 2028

Achèvement de l'étude (Estimé)

31 mars 2028

Dates d'inscription aux études

Première soumission

29 octobre 2026

Première soumission répondant aux critères de contrôle qualité

10 novembre 2026

Première publication (Réel)

16 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 7502
  • R21AG101676 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All datasets that can be shared will be deposited in OpenNeuro, which is an NIH-supported free and open platform for validating and sharing data. De-identified behavioral data, task programs and code, analysis code, experimental protocols, and any additional metadata will be stored and shared on the Open Science Framework. Additional code will be available on GitHub.

Délai de partage IPD

Shared data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the end of the funding period.

Critères d'accès au partage IPD

There are no anticipated factors or limitations that will affect the access, distribution or reuse of the scientific data generated by the proposal.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner